News for Blueprint Medicines Corporation (BPMC)

We recently published a list of 10 Oversold Biotech Stocks to Buy Now.

Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.

Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Call Transcript February 13, 2025Blueprint Medicines Corporation misses on earnings expectations.

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -12.86% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireCAMBRIDGE, Mass., Feb. 13, 2025 -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 mill

Blueprint Medicines (BPMC) is set to release Q4 earnings with projected revenue growth of 101.6% Y/Y.

Is it a good or bad thing when a stock experiences a golden cross technical event?

Blueprint Medicines CEO sells shares worth $159,407

Blueprint Medicines director Jeffrey Albers sells $511,400 in stock

Blueprint Medicines officer Hurley Ariel sells $225,000 in stock

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.

Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday. Shares of Intra-Cellular Therapies, Inc. ITCI rose sharply during Monday's ...

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

PR NewswireCAMBRIDGE, Mass., Dec. 7, 2024 -- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM --

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ETCompany ParticipantsJenna Cohen - Vice...

Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales

The EGFR inhibitors-induced skin disorders market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders. The...

Blueprint Medicines generates strong revenue growth from its FDA-approved product AYVAKIT, reporting $92.5 million in Q1'24 net product revenues. Read more here.